Home/Filings/4/0001628280-25-014192
4//SEC Filing

DuRoss Amy 4

Accession 0001628280-25-014192

CIK 0000834365other

Filed

Mar 19, 8:00 PM ET

Accepted

Mar 20, 7:09 PM ET

Size

7.0 KB

Accession

0001628280-25-014192

Insider Transaction Report

Form 4
Period: 2025-03-14
DuRoss Amy
Director
Transactions
  • Sale

    Common Stock

    2025-03-14$24.96/sh5,632$140,57523,811 total
  • Award

    Common Stock

    2025-03-18+6,87630,687 total
Footnotes (3)
  • [F1]The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.18 to $25.91, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

Issuer

BIOLIFE SOLUTIONS INC

CIK 0000834365

Entity typeother

Related Parties

1
  • filerCIK 0001854968

Filing Metadata

Form type
4
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 7:09 PM ET
Size
7.0 KB